---
title: "002566.SZ (002566.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002566.SZ/news.md"
symbol: "002566.SZ"
name: "002566.SZ"
parent: "https://longbridge.com/zh-CN/quote/002566.SZ.md"
datetime: "2026-03-14T19:44:24.604Z"
locales:
  - [en](https://longbridge.com/en/quote/002566.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002566.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002566.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002566.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002566.SZ/news.md)


# 002566.SZ (002566.SZ) — 相关新闻

### [Haisun Pharmaceutical: Shareholder Wang Xiaoqing plans to reduce holdings by 1.8%](https://longbridge.com/zh-CN/news/273068954.md)
*2026-01-20T10:31:17.000Z*
> Haisun Pharmaceutical announced that shareholder Wang Xiaoqing holds 24.5046 million shares, accounting for 24.5046%, an

### [The proportion of influenza-like cases in the north has reached a four-year high, and the A-share influenza concept has surged. How much real benefit is there?](https://longbridge.com/zh-CN/news/268355382.md)
*2025-12-03T04:19:15.000Z*
> On December 3rd, influenced by the proportion of northern flu cases reaching a four-year high, A-share flu concept stock

### [The flu-resistant concept fluctuates and rises sharply, INT'L GROUP hits the limit up](https://longbridge.com/zh-CN/news/268344462.md)
*2025-12-03T02:12:42.000Z*
> The anti-influenza concept stocks fluctuated and surged during the session, with INT'L GROUP hitting the daily limit. Pr

### [YISHENG PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 24.13 million yuan, a year-on-year decrease of 32.72%](https://longbridge.com/zh-CN/news/262772199.md)
*2025-10-26T11:15:05.000Z*
> According to the Zhitong Finance APP, YISHENG PHARM disclosed its third-quarter report for 2025. The company achieved re

### [YISHENG PHARM General Manager Xue Xiaomin plans to reduce holdings of no more than 416,200 shares](https://longbridge.com/zh-CN/news/240025825.md)
*2025-05-13T12:56:02.000Z*
> According to the Zhitong Finance APP, YISHENG PHARM announced that the company's general manager, Mr. Xue Xiaomin, holds

### [Expanding domestic demand + high growth of traditional Chinese medicine drives YISHENG PHARM's growth into a new stage](https://longbridge.com/zh-CN/news/238030813.md)
*2025-04-29T09:55:00.000Z*
> YISHENG PHARM's diversified layout in the traditional Chinese medicine and consumer sectors has attracted market attenti

### [YISHENG PHARM released its first-quarter performance, with a net profit attributable to the parent company of 11.8616 million yuan, a decrease of 43.56%](https://longbridge.com/zh-CN/news/237113645.md)
*2025-04-23T07:53:04.000Z*
> YISHENG PHARM released its Q1 2025 performance, with operating revenue of 159 million yuan, a year-on-year decrease of 2

### [YISHENG PHARM released its 2024 annual performance, with a net profit attributable to the parent company of 52.0861 million yuan, a year-on-year decrease of 45.02%](https://longbridge.com/zh-CN/news/236373402.md)
*2025-04-17T08:49:13.000Z*
> YISHENG PHARM released its 2024 annual report, with operating revenue of 668 million yuan, a year-on-year decrease of 21

### [YISHENG PHARM: Plans to use no more than 100 million yuan of idle self-owned funds to purchase financial products](https://longbridge.com/zh-CN/news/231179704.md)
*2025-03-10T08:14:00.000Z*
> YISHENG PHARM announced that the company held a board of directors and supervisory board meeting on March 10, 2025, and 

### [YISHENG PHARM released its performance for the first three quarters, with a net profit of 35.8648 million yuan, a year-on-year decrease of 38.66%](https://longbridge.com/zh-CN/news/217860396.md)
*2024-10-25T08:31:06.000Z*
> According to the news from Zhitong Finance and Economics APP, YISHENG PHARM released its third quarter report for 2024.